INDIANAPOLIS, Dec. 30, 2019 /PRNewswire/ — Eli Lilly and Company (NYSE: LLY) today announced the opening of the LIBRETTO-531 clinical trial [NCT04211337] for selpercatinib, also known as LOXO-292, for treatment-naïve RET-mutant medullary thyroid cancer (MTC)...
SOUTH SAN FRANCISCO, Calif., Dec. 30, 2019 (GLOBE NEWSWIRE) — Principia Biopharma Inc. (Nasdaq: PRNB), a late-stage biopharmaceutical company dedicated to bringing transformative oral therapies to patients with significant unmet medical needs in immune-mediated...
(Bloomberg) — A newly approved Chinese drug for Alzheimer’s will start clinical trials in the U.S. and Europe next year as the country’s first novel therapy for the incurable disease seeks global legitimacy. Shanghai Green Valley Pharmaceutical Co. plans to recruit...
MorphoSys AG (FSE: MOR; Prime Standard Segment; MDAX & TecDAX; NASDAQ: MOR) today announced that the first patient has been dosed in a phase 1b clinical study of MorphoSys’ proprietary human anti-CD19 antibody tafasitamab in newly diagnosed diffuse large B...
Selpercatinib (LOXO-292) will be compared with the standard of care in the first ever phase III clinical trial in patients with advanced or metastatic treatment-naïve RET fusion-positive non–small cell lung cancer (NSCLC), according to a press release from Eli Lilly...
Starpharma (ASX:SPL, OTCQX:SPHRY) today announced that AstraZeneca (LSE/STO/NYSE:AZN) has commenced a phase 1 clinical trial of AZD0466 (DEP ® Bcl2/xL conjugate) and the first patient has been successfully dosed. The trial will recruit patients with a range of cancers...
Email
Text